Cardiff Oncology

Turning the Tide on Cancer

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.

Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications with the greatest need for new treatment options.

These programs and our broader development strategy are designed to target tumor vulnerabilities to overcome treatment resistance and deliver superior clinical benefit to patients compared to the SoC.

Onvansertib can work in synergy with many SoC therapies to address a variety of cancer indications

Current
Clinical
Programs

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Combining onvansertib with FOLFIRI/Avastin® to improve objective response rate and progression-free survival.

Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Combining onvansertib with daily Zytiga® to improve disease control and progression-free survival.

Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Combining onvansertib with nanoliposomal irinotecan and 5-FU to improve objective response rate and progression-free survival.